Información del artículo
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
Increaing utilization of bone marrow transplantation. Transplantation. 1986; 40:229-35.
[2]
Human marrow transplantation: an immunological perspective. Adv Inmunol. 1987; 40:379-438.
[3]
Graft-versus-host disease. En: Thomas E.D., Blume K.G., Forman S.J., editors. Hematopoietic cell transplantation. Malden: Blackwell Science Inc.; 1998. 515-36.
[4]
The biology of graft-versus-host reactions. New York: Academic Press; 1966. 21-78
[5]
Gastrointestinal and hepatic complications. En: Thomas E.D., Blume K.G., Forman S.J., editors. Hematopoietic cell transplantation. Malden: Blackwell Science Inc.; 1998. 627-58.
[6]
Graft-versus-host disease: new directions for a persistent problem. Blood. 1994; 84:2061-7.
[7]
Mismatches of minor histocompatibility antigens between HLA-identical donors and reciplents and the development of GVHD after bone marrow transplantation. N Engl J Med. 1966; 334:281-5.
[8]
Acute-versus-host-disease: pathobiology and management. Experimental Hematol. 2001; 29:259-77.
[9]
Graft-versus host disease. N Engl J Med. 1991; 324:667-74.
[10]
Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999; 13:1091-112.
[11]
Carreras E. Implicaciones de la enfermedad injerto contra huésped. Gastroenterol Hepatol. 200;23:354-60.
[12]
Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2003; 54:29-52.
[13]
The primacy of gastrointestinal tract as a target organ os acute graft-versus-host disease. Blood. 2000; 95:2754-9.
[14]
Intestinal graft-versus-host disease. Mechanism and management. Drugs. 2003; 63:1-15.
[15]
Athogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res. 2000; 9:299-306.
[16]
The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003; 78:181-7.
[17]
Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003; 21:149-61.
[18]
The immune system (first of two parts). N Engl J Med. 2000; 343:37-49.
[19]
La importancia del sistema inmune innato. Rev Esp de Enferm Dig. 2001; 93:721-30.
[20]
Innate immunity. N Engl J Med. 2004; 343:338-43.
[21]
CpG DNA: a potent signal for growth, activation and maturation of human dendritic cells. Proc Natl Acad Sci. 1999; 96:9305-10.
[22]
Total body irradiation and acute graft-versus-host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood. 1997; 90:3204-13.
[23]
Understanding the alloresponse. New approaches to graft-versus-host disease prevention. Sem Hematol. 2002; 39:15-22.
[24]
Role of T cell subsets in lethal graft-versus- host disease directed to class I versus class II antigens. J Exp Med. 1988; 167:556-69.
[25]
The immune system (second of two parts). N Engl J Med. 2000; 343:108-17.
[26]
Tolerance and autoimmunity. N Emgl J Med. 2001; 344:655-64.
[27]
Peripheral deletion afther bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive. Cell Death J Immunol. 2001; 166:2311-6.
[28]
Paradigm shift for graft-versus-host disease. Bone Marrow Transplant. 1994; 14:183-4.
[29]
Tumor necrosis factor can induce both apoptosis and necrotic forms of cell lysis. J Immunol. 1988; 141:2629-34.
[30]
Interleukin 1 is a critical effector molecule during cytokine dysregulation in graftversus- host disease. Transplantation. 1993; 56:1518-23.
[31]
Nitric oxide production in host-versus-graft and graft-versus-host reaction in rat. J Clin Invest. 1992; 90:79-683.
[32]
How do cytotoxic lymphocytes kill their targets?. Curr Opin Immunol. 1998; 10:581-7.
[33]
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994; 265:528-30.
[34]
Cytolytic pathways in haemopoietic stem-cell transplantation. Nature Rev Inmmunol. 2002; 2:273-81.
[35]
Novel therapeutics for the treatment of graftversus- host disease. Expert Opin Investig Drugs. 2002; 11:1271-80.
